Italian pharma company Chiesi Farmaceutici announced this week that it completed the acquisition of Amryt Pharma, a Dublin-based biopharma focusing on treatments for rare and orphan diseases.
The deal — first announced in January — includes an upfront payment of $1.25 billion and could fetch Amryt up to $1.48 billion total.
“Amryt has unique and clinically differentiated products and additional promising drugs in its pipeline, and, as a benefit corporation certified B Corp, Chiesi has a patient-centric and sustainable model in place to make these treatments available to even more patients who need them,” said Chiesi’s head of global rare diseases Giacomo Chiesi.
Included in the deal are Amryt's three FDA-approved treatments: Juxtapid for omozygous familial hypercholesterolemia, Myalept for lipodystrophy and Mycapssa for acromegaly. Amryt also brings promising pipeline treatments — among them, a treatment for dystrophic epidermolysis bullosa and a topical treatment for epidermolysis bullosa simplex.
Last month, Chiesi Group announced a partnership with Swedish biotech Affibody AB to develop and commercialize treatments for respiratory illnesses.
